Research Analysts Offer Predictions for CRBP FY2030 Earnings

Key Points

• HC Wainwright projects FY2030 EPS of ($1.21) for Corbus, materially less negative than the consensus estimate of ($4.23) per share.
• Corbus beat quarterly EPS expectations (reported ($1.25) vs. est. ($1.78)), its stock is trading around $10.04 (up ~5.1%), and analysts hold a consensus "Moderate Buy" with an average target price of $43.71.
• Insiders sold a total of 35,729 shares (~$390,245) over the past three months while institutional investors own about 64.64% of the company.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Monday, March 9th. HC Wainwright analyst A. Maldonado forecasts that the biopharmaceutical company will post earnings of ($1.21) per share for the year. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share.

Several other analysts have also recently weighed in on the stock. Oppenheimer increased their price target on shares of Corbus Pharmaceuticals from $53.00 to $57.00 and gave the company an "outperform" rating in a research note on Tuesday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada decreased their price objective on Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a report on Thursday, November 13th. Finally, Jefferies Financial Group raised Corbus Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $43.71.

Corbus Pharmaceuticals Trading Up 5.1%

Corbus Pharmaceuticals stock opened at $10.04 on Wednesday. The company has a 50-day moving average price of $8.19 and a 200 day moving average price of $10.54. Corbus Pharmaceuticals has a 12-month low of $4.64 and a 12-month high of $20.56. The stock has a market cap of $176.20 million, a P/E ratio of -1.68 and a beta of 2.84.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, beating the consensus estimate of ($1.78) by $0.53.

Insider Buying and Selling

In related news, major shareholder Cormorant Asset Management, Lp sold 30,029 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $11.46, for a total transaction of $344,132.34. Following the completion of the transaction, the insider owned 2,344,971 shares of the company's stock, valued at approximately $26,873,367.66. This trade represents a 1.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Dominic Smethurst sold 3,285 shares of Corbus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total transaction of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares of the company's stock, valued at $775,725.83. This trade represents a 3.31% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 35,729 shares of company stock worth $390,245 over the last three months. Insiders own 4.00% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd purchased a new position in shares of Corbus Pharmaceuticals during the fourth quarter worth $54,000. ADAR1 Capital Management LLC acquired a new position in Corbus Pharmaceuticals during the 3rd quarter worth about $129,000. Virtu Financial LLC acquired a new position in Corbus Pharmaceuticals during the 4th quarter worth about $88,000. Barclays PLC boosted its holdings in Corbus Pharmaceuticals by 280.0% during the 4th quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company's stock valued at $120,000 after acquiring an additional 10,874 shares during the period. Finally, Hudson Bay Capital Management LP purchased a new position in Corbus Pharmaceuticals during the 4th quarter valued at about $139,000. 64.64% of the stock is currently owned by institutional investors and hedge funds.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.